Understanding Advanced Prostate Cancer

/Understanding Advanced Prostate Cancer

Cognition and Hormone Therapy (ADT)

There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well as my own personal experience, I must fall in line and agree with an online published study that shows that men on ADT are likely to experience cognitive impairment of some type. The study was small, as all of the other studies have been, followed [...]

A Brief Update of the Current Landscape of Bone Targeted Therapies for Prostate Cancer

Prostate cancer tends to metastasize to bones as opposed to soft tissue and other organs.   We have no idea why it does have a preference for bone, but it does. Developing bone metastases in prostrate cancer is a very strong negative prognostic indicator. Prostate cancer’s tendency to favor bone over soft tissue causes significant morbidity and mortality for men. Bone metastasis has a major impact on quality of life and longevity for men with prostate cancer and it needs to be aggressively treated. Because of this, prostate cancer survivors need to focus on drugs that slow down or interfere with [...]

Efficacy of Enzalutamide in Castrate-Resistant Prostate Cancer in Men with Visceral Metastases

We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM clinical trial have demonstrated that treatment with the androgen receptor inhibitor enzalutamide (Xtandi) resulted in significant improvements in outcomes for men with mCRPC. This blog post discusses the efficacy of enzalutamide among men from the AFFIRM trial who had visceral disease. Men who were in [...]

Some Factors That Might Be Predictors of the Duration of Abiraterone Acetate in Men with Castration-Resistant Prostate Cancer

Being able to make better decisions about drug sequencing and combinations has become one of the current hot topics in prostate cancer research. Given that we have a number of newer drugs to use this is an important clinical issue as we make important treatment decisions. Making these clinical decisions is tough.  The fact is that prostate cancer is a very heterogeneous disease and so  drug  responses are not consistent. Compounded by the fact that none of our treatments are effective for an extended time period knowing how to accurately predict drug response is vital. One  example of research dealing [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー